XBiotech Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

XBiotech şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-0.08%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-0.08%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

We Think Some Shareholders May Hesitate To Increase XBiotech Inc.'s (NASDAQ:XBIT) CEO Compensation

Jun 16

XBiotech (NASDAQ:XBIT) Is In A Good Position To Deliver On Growth Plans

May 11

Read This Before Buying XBiotech Inc. (NASDAQ:XBIT) Shares

Mar 18

Here's Why We Don't Think XBiotech's (NASDAQ:XBIT) Statutory Earnings Reflect Its Underlying Earnings Potential

Jan 08

XBiotech's influenza-COVID-19 therapeutic cocktail shows effective anti-virus activity

Nov 19

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: XBIT şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: XBIT şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

XBiotech Piyasaya Karşı Temettü Getirisi

XBIT temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (XBIT)	n/a
Pazarın Alt %25'i (US)	1.3%
Pazarın En İyi %25'i (US)	4.2%
Sektör Ortalaması (Biotechs)	2.3%
Analist tahmini (XBIT) (3 yıla kadar)	n/a

Önemli Temettü: XBIT şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, XBIT şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: XBIT şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: XBIT herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

XBiotech Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Is XBiotech (NASDAQ:XBIT) Weighed On By Its Debt Load?

XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer

XBiotech: Several Shots On Goal In Big Target Market Indications

Is XBiotech (NASDAQ:XBIT) Using Debt In A Risky Way?

XBiotech Inc., Annual General Meeting, Jun 20, 2024

New minor risk - Share price stability

XBiotech Inc. announced that it expects to receive $10 million in funding

Xbiotech Appoints Alan Kivitz M.D. Lead Investigator & Study Chairman for Its Clinical Research Program for Natrunix in Rheumatoid Arthritis

Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.42 loss in 3Q 2022)

Xbiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, A Novel Candidate Therapy for Stroke

Xbiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer

First half 2023 earnings released: US$0.41 loss per share (vs US$0.56 loss in 1H 2022)

First quarter 2023 earnings released: US$0.13 loss per share (vs US$0.18 loss in 1Q 2022)

Full year 2022 earnings released: US$1.08 loss per share (vs US$0.58 loss in FY 2021)

XBiotech Inc. Announces Executive Changes

We're Not Very Worried About XBiotech's (NASDAQ:XBIT) Cash Burn Rate

Insufficient new directors

Third quarter 2022 earnings released: US$0.42 loss per share (vs US$0.11 loss in 3Q 2021)

We're Hopeful That XBiotech (NASDAQ:XBIT) Will Use Its Cash Wisely

XBiotech Inc. Announces First Patient Enrolled into the French National Cancer Institute Sponsored Phase I/Ii/Iii Clinical Study for Natrunix™ Therapy for Colorectal Cancer

Second quarter 2022 earnings released: US$0.38 loss per share (vs US$0.17 loss in 2Q 2021)

XBiotech Inc.(NasdaqGS:XBIT) dropped from Russell 2000 Dynamic Index

XBiotech Announces Successful Completion of Phase I Portion of Pancreatic Cancer Study

XBiotech Inc., Annual General Meeting, Jun 22, 2022

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

XBiotech Announces First Patient Enrolled in Phase I Clinical Trial for Novel Arthritis Therapy Natrunix-SQ

Insufficient new directors

Third quarter 2021 earnings released: US$0.11 loss per share (vs US$0.087 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.17 loss per share (vs US$0.24 loss in 2Q 2020)

Board Member exercised options to buy US$452k worth of stock.

XBiotech Inc. Announces First Patient Enrolled in Clinical Trial Evaluating XB2001 for the Treatment of Pancreatic Cancer

We Think Some Shareholders May Hesitate To Increase XBiotech Inc.'s (NASDAQ:XBIT) CEO Compensation

XBiotech (NASDAQ:XBIT) Is In A Good Position To Deliver On Growth Plans

French National Cancer Institute and XBiotech Join forces to Conduct Innovative Phase II/III Adaptive Multicenter Clinical Study for XBiotech’s New Cancer Drug for Colorectal Cancer

Founder exercised options to buy US$9.8m worth of stock.

Read This Before Buying XBiotech Inc. (NASDAQ:XBIT) Shares

New 90-day high: US$19.83

XBiotech Candidate True Human™ COVID-19 Therapy Found to Target Highly Infectious Emerging Strain

Here's Why We Don't Think XBiotech's (NASDAQ:XBIT) Statutory Earnings Reflect Its Underlying Earnings Potential

New 90-day low: US$16.72

Independent Director notifies of intention to sell stock

Xbiotech Data Shows Effective Anti-Virus Activity for True Human Antibodies in Its Candidate Influenza-Covid-19 Therapeutic Cocktail

XBiotech's influenza-COVID-19 therapeutic cocktail shows effective anti-virus activity

XBiotech Developing True Human Antibody Combination as Candidate Treatment for Influenza-COVID-19 Co-Infections

New 90-day high - US$19.95

New 90-day high - US$19.57

New 90-day high - US$16.08

XBiotech Inc.(NasdaqGS:XBIT) dropped from Russell 3000 Growth Index

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin